ABSTRACT
Polygenic risk scores (PRS) have attenuated cross-population predictive performance. As existing genome-wide association studies (GWAS) were predominantly conducted in individuals of European descent, the limited transferability of PRS reduces its clinical value in non-European populations and may exacerbate healthcare disparities. Recent efforts to level ancestry imbalance in genomic research have expanded the scale of non-European GWAS, although they remain under-powered. Here we present a novel PRS construction method, PRS-CSx, which improves cross-population polygenic prediction by integrating GWAS summary statistics from multiple populations. PRS-CSx couples genetic effects across populations via a shared continuous shrinkage prior, enabling more accurate effect size estimation by sharing information between summary statistics and leveraging linkage disequilibrium (LD) diversity across discovery samples, while inheriting computational efficiency and robustness from PRS-CS. We show that PRS-CSx outperforms alternative methods across traits with a wide range of genetic architectures and cross-population genetic correlations in simulations, and substantially improves the prediction of quantitative traits and schizophrenia risk in non-European populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
T.G. is supported by NIA K99/R00AG054573. H.H. acknowledges support from NIDDK K01DK114379, NIMH U01MH109539, Brain & Behavior Research Foundation Young Investigator Grant, the Zhengxu and Ying He Foundation, and the Stanley Center for Psychiatric Research. A.R.M. is supported by NIMH K99/R00MH117229.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Collection of the UK Biobank (UKBB) data was approved by the UKBB's Research Ethics Committee. UKBB GWAS summary statistics were released by the Neale Lab and are publicly available (http://www.nealelab.is/uk-biobank). UKBB individual-level data used in the present work were obtained under application #32568. Biobank Japan (BBJ) GWAS summary statistics are publicly available on the BBJ website (http://jenger.riken.jp/en/result). The PAGE study GWAS summary statistics are publicly available on the GWAS Catalog (https://www.ebi.ac.uk/gwas/downloads/summary-statistics). Schizophrenia GWAS summary statistics for the European and East Asian populations are publicly available on the Psychiatric Genomics Consortium (PGC) website (https://www.med.unc.edu/pgc/download-results/). The use of schizophrenia individual-level data of East Asian ancestry in the present work was approved by the Stanley Global Asia Initiatives. The following institutions provided ethics oversight for the collection of schizophrenia East Asian data: Domain Specific Review Board (Singapore); University of Hong Kong; Fujita Health University; RIKEN Center for Integrative Medical Sciences; Nagoya University; Osaka University; Niigata University; Bio-X Institutes of Shanghai Jiao Tong University; University Medical Center Utrecht; The University of Western Australia; The University of Indonesia; Peking University Sixth Hospital; National Taiwan University; Samsung Medical Center; Chonnam National University Hospital; Tokyo Metropolitan Institute of Medical Science and affiliated institutions; Harvard Harvard T.H. Chan School of Public Health.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Email: chinsir{at}sjtu.edu.cn (S.Q.); hhuang{at}broadinstitute.org (H.H.); tge1{at}mgh.harvard.edu (T.G.)
Data Availability
Publicly available data were downloaded from the following databases: 1000 Genomes Phase 3 reference panels: https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html; Genetic map for each subpopulation: ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rates; UKBB summary statistics: http://www.nealelab.is/uk-biobank (GWAS round 2 was used in this study); BBJ summary statistics: http://jenger.riken.jp/en/result; PAGE summary statistics were downloaded from the GWAS Catalog: https://www.ebi.ac.uk/gwas/downloads/summary-statistics; PGC wave 2 schizophrenia EUR GWAS (49 EUR samples): https://www.med.unc.edu/pgc/download-results/scz; Schizophrenia EAS summary statistics are available upon request to PGC Schizophrenia Work Group. Schizophrenia individual-level data of East Asian ancestry are available upon reasonable request with regulatory/compliance review to the Stanley Global Asia Initiatives: zguo@broadinstitute.org.
